Neutrogena Skin Clearing Blemish Concealer - Buff 09, Neutrogena Skin Clearin...

Description

SkinClearing blemish concealer is formulated with MICROCLEAR® technology, which enhances the delivery of Salicylic Acid, a recognized blemish treatment. This product effectively conceals and treats blemishes while providing natural-looking coverage. Manufactured by Neutrogena®, it is available in a net weight of 0.05 ounces (1.4 grams).

Uses and Indications

This drug is indicated for the treatment of acne. It is intended for use in patients diagnosed with this condition to help manage and reduce the severity of acne symptoms.

Dosage and Administration

Healthcare professionals should ensure that the skin is thoroughly cleansed prior to the application of this product. The recommended application involves covering the entire affected area with a thin layer. This can be done one to three times daily, depending on the patient's needs and the physician's guidance.

To minimize the risk of excessive drying of the skin, it is advisable to initiate treatment with one application per day. Based on the patient's response and tolerance, the frequency may be gradually increased to two or three times daily as necessary or as directed by a healthcare provider.

In cases where bothersome dryness or peeling occurs, it is recommended to reduce the frequency of application to once a day or every other day to alleviate these symptoms.

Contraindications

There are no specific contraindications listed for this product. However, it is essential to keep the product out of reach of children. In the event of accidental ingestion, seek medical assistance or contact a Poison Control Center immediately.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to avoid concurrent use of this product with other topical acne medications, as this may increase the likelihood of skin irritation and dryness. In the event of irritation, it is recommended that patients limit their use to one topical acne medication at a time.

In cases of accidental eye contact, it is imperative to flush the eyes thoroughly with water to mitigate potential harm.

This product should be kept out of reach of children. In the event of ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is advised.

Side Effects

Patients using this product should be aware that it is intended for external use only. The most common adverse reactions reported include skin irritation and dryness, particularly when used concurrently with other topical acne medications. To minimize the risk of these reactions, it is advised that patients use only one topical acne medication at a time.

In the event of eye contact, it is crucial to flush the eyes thoroughly with water to mitigate potential irritation. These precautions are important to ensure the safe and effective use of the product.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications is recommended to alleviate symptoms. Monitoring for signs of skin irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Neutrogena Skin Clearing Blemish Concealer - Buff 09, Neutrogena Skin Clearing Blemish Concealer - Fair 05, Neutrogena Skin Clearing Blemish Concealer - Light 10, Neutrogena Skin Clearing Blemish Concealer - Medium 15 (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely when using this medication. It is essential to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is advised.

For topical application, it is recommended to initiate treatment with one application daily to minimize the risk of excessive skin drying. Dosage may be gradually increased to two or three times daily as needed or directed by a healthcare professional. If patients experience bothersome dryness or peeling, the frequency of application should be reduced to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Safety during pregnancy has not been established for this medication. It is not recommended for use during pregnancy due to potential risks to the fetus. Pregnant patients or those planning to become pregnant should consult a healthcare provider before using this medication to discuss potential risks and benefits.

Lactation

There are no specific statements regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, there is no available data on the excretion of this medication in breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the absence of information when advising lactating mothers about the use of this medication.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise caution and consider the overall clinical context when prescribing this medication to patients with liver problems, as the absence of specific guidance necessitates careful evaluation of potential risks and benefits.

Overdosage

In the event of an overdosage, immediate medical assistance is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical help or contact a Poison Control Center without delay.

Prompt intervention is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved; therefore, a thorough assessment by a medical professional is recommended to determine the appropriate course of action.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. It is imperative that healthcare providers remain vigilant and prepared to address any complications that may arise from an overdosage scenario.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No specific postmarketing experience details have been reported. As such, there are no additional adverse events or rare case reports to summarize at this time.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. In the event of swallowing the medication, patients should seek medical assistance or contact a Poison Control Center immediately.

Patients should be informed that the use of this medication may lead to skin irritation and dryness, particularly if they are using another topical acne medication concurrently. It is recommended that patients use only one topical acne medication at a time to minimize the risk of irritation.

Additionally, healthcare providers should instruct patients on the importance of avoiding eye contact with the medication. If contact occurs, patients should be advised to flush the eyes thoroughly with water to ensure safety and reduce potential discomfort.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature to maintain its integrity and efficacy. No special handling requirements are noted; however, standard precautions should be observed to ensure optimal storage conditions.

Additional Clinical Information

The product is administered topically. Clinicians should advise patients to keep the medication out of reach of children and to seek medical assistance or contact a Poison Control Center immediately if swallowed. In the event of eye contact, patients should flush the area thoroughly with water.

Patients are cautioned that the use of this topical acne medication in conjunction with other topical acne treatments may increase the likelihood of skin irritation and dryness. If irritation occurs, it is recommended that only one topical acne medication be used at a time.

Drug Information (PDF)

This file contains official product information for Neutrogena Skin Clearing Blemish Concealer - Buff 09, Neutrogena Skin Clearing Blemish Concealer - Fair 05, Neutrogena Skin Clearing Blemish Concealer - Light 10, Neutrogena Skin Clearing Blemish Concealer - Medium 15, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)